Accent Biosciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 3.00 M
as on 16-11-2024
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 58.50 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 332.85%
(FY 2023)
About Accent Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹58.50 Cr.
Ghanshyam Patel, Vasant Patel, Bhupeshkumar Rasiklal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299GJ2021PTC119892
- Company No.
119892
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Accent Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhupeshkumar Rasiklal  | Director | 02-Feb-2021 | Current |
| Ghanshyam Patel | Director | 02-Feb-2021 | Current |
| Vasant Patel | Director | 02-Feb-2021 | Current |
| Nilesh Patel | Director | 02-Feb-2021 | Current |
Financial Performance and Corporate Structure Insights of Accent Biosciences.
Accent Biosciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Accent Biosciences?
In 2023, Accent Biosciences had a public holding of 62.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 13 Jan 2023 | ₹26.75 Cr | Open |
Hdfc Bank Limited Creation Date: 05 Jan 2023 | ₹31.75 Cr | Open |
How Many Employees Work at Accent Biosciences?
Accent Biosciences has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Accent Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Accent Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
